Brain stimulation technologies, both invasive and non-invasive, have been successful in acquiring FDA approval for several indications within neuropsychiatry to include depression, Parkinson's disease, and others. Unfortunately, despite extensive testing, brain stimulation has failed to be part of the clinical toolbox for treatment of stroke or brain injury. Epidural stimulation showed promise in early stages of validation but failed in phase III studies with a major limitation of delayed timing of intervention(1). Surgical implantation of epidural electrodes is invasive and cannot be performed in the very early stages after stroke when the recovery is dynamic and robust. This led to exploration of less invasive alternative options. In their recently published study in Nature Biomedical Engineering, Opie et al (2) devised an innovative approach for cortical stimulation using "Stentrodes", electrode carrying stents that are implanted within the cerebral venous system via endovascular route. This study was conducted in an ovine model where Stentrodes were implanted in the superior sagittal sinus. The superior sagittal sinus (SSS) in sheep and central sulcal vein in human are comparable in diameter and overlay the primary motor cortex providing an optimal target for electrode implantation. As reported by the authors, stent occlusion did not occur within the 30 days of pre-stimulation monitoring although it is unclear whether antiplatelet agents were used, and stents were successfully incorporated into the vessel wall within the 28 days of stabilization period.
Electrical stimulation via electrodes mounted on the stent provoked motor response in the muscles of face, neck and forelimbs (2) .
As a proof-of-concept study, this pre-clinical study demonstrated that endovascular cortical stimulation has comparable success rate to invasive subdural or intraparenchymal stimulation without the need to perform invasive craniotomy to place surface stimulators. This advantage is specifically significant in the context of stroke or traumatic brain injury when patients are at high Despite all enthusiasm, the findings of this study should still be interpreted with caution prior to translation and testing in human subjects especially in the context of stroke and brain injury.
First, the cerebral venous anatomy is different between sheep and humans as previously described by authors(3) and access to central sulcal vein is expected to constitute significant technical challenge in human subjects compared to access to the SSS leading to higher morbidity. Secondly, the use of antiplatelet therapy is a common requirement for all endovascular interventions that involve intravascular stent implantation to prevent thrombosis prior to endothelialization (4) . Stent thrombosis relates to multiple factors including vessel caliber, stent geometry regarding, the amount of metal exposed to blood flow and the material used for the device. The endovascular field has evolved rapidly, currently we have commercially available (outside US, and currently investigational device in US) braided stents, where the filaments used are treated with phosphorylcholine, decreasing the amount of thrombin generated and the platelet aggregation, these technological improvements will theoretically require less antiplatelet therapy. (5) Notably, compared to transverse sinus stenting, in-stent thrombosis within the SSS or central sulcal vein is likely to lead to devastating complication with cortical venous infarcts and cerebral hemorrhage. Thus, prior to the evaluation of efficacy, the safety of this approach needs to be carefully demonstrated. One possible avenue would be to test safety of the device in patients undergoing transverse sinus stenting (larger vessel) in terms of thrombosis rates or other complications. Compared to arterial implantation, one advantage of the venous route is the lack of smooth muscle layers. Stimulation of veins is unlikely to provoke vasospasm as would be expected with arterial stimulation; however, electrical stimulation may still provoke the coagulation cascade intravascular especially when higher amplitude currents are used.
Regardless of the barriers and challenges, we still expect great opportunities for using cortical stimulation via cerebral venous access in multitude of neurological disorders. The first-in-human use of Stentrodes have been registered in clinicaltrials.gov(6); we are looking forward to exciting results in the not-too-distant future.
